The inhaled form, formulated with Industry leading mSAS ® technology, is delivered to deep lung up to 4X more than other technologies. Extensive histopathology studies of the entire respiratory tract, even at high doses, demonstrate no signs of irritation representing excellent tolerability and minimal risk of cough reflex. These studies confirm an important advantage in terms of treatment compliance in IPF patients. From pharmacokinetic studies only 1/3 of the inhaled dose passes out of the lung into the bloodstream where it is cleared very quickly thus minimizing any potential systemic side effects. Favorable high retention time in rat lung tissues as well as favorable kinetics were observed for inhaled INHAL-101.